scholarly journals Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study

2018 ◽  
Vol 10 (1) ◽  
Author(s):  
Maarten Timmers ◽  
Johannes Rolf Streffer ◽  
Alberto Russu ◽  
Yushin Tominaga ◽  
Hiroko Shimizu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Bace1 Inhibitor ◽  
Early Alzheimer’S Disease

scholarly journals Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

2012 ◽  
Vol 4 (5) ◽  
pp. 43 ◽  
Author(s):  
John M Ringman ◽  
Sally A Frautschy ◽  
Edmond Teng ◽  
Aynun N Begum ◽  
Jenny Bardens ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled study

Neurology ◽  
2003 ◽  
Vol 60 (7) ◽  
pp. 1071-1076 ◽  
Author(s):  
O.M. Wolkowitz ◽  
J.H. Kramer ◽  
V.I. Reus ◽  
M.M. Costa ◽  
K. Yaffe ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Dhea Treatment

DGAVP (Org 5667) in early Alzheimer's disease patients: An international double-blind, placebo-controlled, multicenter trial

Neurology ◽  
1990 ◽  
Vol 40 (7) ◽  
pp. 1099-1099 ◽  
Author(s):  
E. Ch. Wolters ◽  
P. Riekkinen ◽  
A. Lowenthal ◽  
J. J. V. der Plaats ◽  
J.M.T. Zwart ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Multicenter Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Early Alzheimer’S Disease
Sign in / Sign up

Export Citation Format

Share Document